-
-
-
-
-
-
-
UZEDY® Accelerates: 2025 Revenue Outlook Raised to $190–$200M (from ~$160M); Olanzapine LAI on Track for Submission in 2025
-
-
-
-
-
-
-
Medincell Publishes Its Consolidated Half-year Financial Results
-
-
-
-
-
-
-
Medincell to Present at the 2024 Jefferies Global Healthcare Conference, June 4 to 6, 2024, New York
-
-
-
-
-
-
-
MedinCell Applauds Teva and Royalty Pharma Collaboration to Further Accelerate Olanzapine LAI Program (Codename: mdc-TJK or TEV-‘749)
-
-
-
-
-
-
-
MedinCell’s partner Teva confirms expectation for approval and commercialization in the US in H1 2023 for mdc-IRM/TEV46000
-
-
-
-
-
-
-
MedinCell Announces Fiscal Year Consolidated Results
-
-
-
-
-
1,198,731 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

